CDKL5 deficiency is a severe neurological disorder caused by mutations in the X-linked Cyclin-Dependent Kinase-Like 5 gene (CDKL5). The predominant human CDKL5 brain isoform is a 9.7 kb transcript comprised of 18 exons with a large 6.6 kb 3'-untranslated region (UTR). Mammalian models of CDKL5 disorder are currently limited to mouse, and little is known about Cdkl5 in other organisms used to model neurodevelopmental disorders, such as rat. In this study we characterise, both bioinformatically and experimentally, the rat Cdkl5 gene structure and its associated transcript isoforms. New exonic regions, splice sites and UTRs are described, confirming the presence of four distinct transcript isoforms. The predominant isoform in the brain, which we name rCdkl5_1, is orthologous to the human hCDKL5_1 and mouse mCdkl5_1 isoforms and is the most highly expressed isoform across all brain regions tested. This updated gene model of Cdkl5 in rat provides a framework for studies into its protein products and provides a reference for the development of molecular therapies for testing in rat models of CDKL5 disorder.
Introduction
CDKL5 deficiency (Mendelian Inheritance in Man, MIM: 300203) is a rare, X-linked genetic disorder that results in early onset seizures and neurodevelopmental impairment. A range of phenotypes are associated with the disorder, and are a result of mutations in the CyclinDependent Kinase-Like 5 gene, CDKL5, located on the X-chromosome (Xp22.13) (Kalscheuer et al., 2003; Fehr et al., 2013) . Early-onset seizures are common, and phenotypes may also include other features, such as stereotypic hand movements, severe psychomotor impairment, general hypotonia and visual impairments (Kalscheuer et al., 2003; Tao et al., 2004; Artuso et al., 2010; Intusoma et al., 2011; Moseley et al., 2012) .
Many of these features, such as impaired motor control, altered behaviour, abnormal eye tracking and general hypoactivity are recapitulated in the two Cdkl5 knockout (KO) mouse models that have been reported (Wang et al., 2012; Amendola et al., 2014) . However, spontaneous infantile seizures, a defining feature of the disorder in patients, are not observed in mice. Rats offer an alternative model in the study of neurodevelopmental disorders, and recent work using a rat model of Fragile X Syndrome has allowed a number of key aspects of the disorder to be investigated, such as complex cognitive and social functions (Till et al., 2015) . These biological and technical advantages, coupled with the fact that mice fail to recapitulate the spontaneous seizures that define CDKL5 disorder, suggests that the development of another rodent and larger species models of CDKL5 disorder may be beneficial to the field. In advance of this however, it is important to assess differences in the Cdkl5 gene between species.
In a recent study we characterised the structure of the human CDKL5 and mouse Cdkl5 genes, identifying a number of transcript isoforms resulting from alternative splicing (Hector et al., 2016) . In the rat, two different transcript isoforms have been identified to date; CDKL5a and CDKL5b (GenBank accession numbers FJ807484 and GU351881, respectively) (Chen et al., 2010) . Although these transcripts were thought to be expressed primarily in the brain, neither is orthologous to the predominant brain isoform of CDKL5 in human and mouse, a large 9.7 kb transcript comprised of 18 exons with a large 6.6 kb 3'-UTR. At present the rat Cdkl5 gene structure, transcript set and protein isoforms are not fully understood. In this study we sought to characterise the gene structure of Cdkl5 in rat using bioinformatic analyses and molecular methods, to identify all transcript isoforms and the predicted suite of resultant protein isoforms, and to compare rat Cdkl5 with its human and mouse orthologues.
Materials and Methods

RNA-seq data analysis
Bioinformatic and molecular analyses were performed as described previously to investigate the transcript isoforms of rat Cdkl5 (Hector et al., 2016) . In brief, RNA-seq datasets were analysed (rat brain GEO sample ID's GSM1020666, GSM1020675 and GSM1020684; rat testis GEO sample ID's GSM1020674, GSM1020683, GSM1020692 (Merkin et al., 2012)) and mapped to the rat genome using the STAR read aligner, version 2.4.2a.
RNA isolation
Rat total RNA was isolated from tissues obtained from 3 month old wild-type male Sprague Dawley rats using the RNeasy Lipid Tissue Kit (Qiagen). Animal samples were collected in accordance with the European Communities Council Directive (86/609/EEC) and with the terms of a project license under the UK Scientific Procedures Act (1986). The quality and quantity of isolated RNA was analysed using the RNA 6000 kit on a 2100 Bioanalyzer (Agilent).
RT-PCR and Quantitative RT-PCR
Total RNA was reverse transcribed using Superscript III (Life Technologies), according to the manufacturer's protocol, in 20 μl reactions containing 200 ng of RNA template and 1 μM random hexamers. Reactions were then incubated with 2 units of RNaseH (Life Technologies) at 37°C for 20 min). End-point PCR was performed using Maxima Hot Start Green (Thermo Scientific), according to the manufacturer's protocol, in 50 μl reactions containing 500 nM gene-specific primers, and products visualised on agarose gels. PCR was performed under the following cycling conditions: an initial denaturation at 95°C for 2 min, then 35 cycles of 95°C for 30 s, 58°C for 30 s and 72°C for 60 s, followed by a final extension of 72°C for 7 min. SYBR Green PCR reactions were carried out using the PerfeCTa SYBR kit (Quanta Bioscience), according to the manufacturer's protocol, in 20 μl reactions using 1/20th of the first-strand synthesis reaction and 300 nM gene-specific primers. PCR was performed under the following cycling conditions on an Mx3005P thermocycler (Agilent Technologies): an initial denaturation at 95°C for 30 s, then 40 cycles of 95°C for 10 s and 60°C for 60 s, followed by a dissociation curve. Appropriate controls were included as recommended by the MIQE guidelines. The primers used in this study are provided in Figure S1 .
Rapid amplification of cDNA ends (RACE)
Rapid Amplification of cDNA Ends was performed using the 3'-RACE & 5'-RACE System for Rapid Amplification of cDNA ends (Life Technologies), according to the manufacturer's protocol. PCR amplicons were cloned using the TOPO TA Cloning Kit (Life Technologies), individual colonies were grown in L-Broth, and plasmids were purified using the PureYield Plasmid Miniprep System (Promega) and then sequenced (Source BioScience). Sequence comparisons were performed using BLASTN (http://blast.ncbi.nlm.nih.gov/).
Results
Rat Cdkl5 transcript isoforms
In order to identify all Cdkl5 splicing events, rat tissue-specific RNA-seq datasets were analysed and sensitive alignment tools were used to detect reads mapping across all potential splice junctions. To validate these exon boundaries and splice junctions experimentally, RT-PCR was used to generate products spanning multiple exons and PCR products sequenced. Using this approach, 23 discrete exons were detected, including two novel exons at the 5' end of the gene, 1a and 1b ( Fig. 1) . Exon boundaries and cryptic splice sites were confirmed, and the composition of each specific isoform was elucidated, so isoform-specific RT-PCR assays could be designed (design details are provided in Fig. S1 ).
Combined, the RNA-seq and RT-PCR data confirmed the existence of four distinct transcript isoforms containing distinct protein-coding regions (Fig. 1A, Table 1 ). In accordance with new nomenclature recommendations (Hector et al., 2016) , we have named these rCdkl5_1, rCdkl5_2, rCdkl5_9, and rCdkl5_10. The composition of each transcript, the exon boundaries and chromosomal sequence coordinates are detailed in Table 2. RNA-seq analysis also predicted two rare transcripts containing additional exons that were detected and confirmed by sequencing of RT-PCR amplicons (data not shown). Mammalian Cdkl5 is unusual in having an embedded gene, Gja6, located within one of its introns and transcribed in the same direction, and one of these additional rCdkl5 transcripts incorporates a 125 bp portion of exon 2 of Gja6. The second rare transcript incorporates a 117 bp exon, located in rCdkl5 intron 12, which is predicted to be part of a Long Interspersed Nuclear Element-1 (LINE-1) retrotransposon (analysis was carried out using BLASTN and RepeatMasker: http://www.repeatmasker.org/). As such, it was concluded that both of these rare transcripts resulted from aberrant splicing events and they were excluded from further analysis. In addition, no rat orthologues of hCDKL5_3 and hCDKL5_4 were identified. The cryptic splice donor site in exon 11 used by these human isoforms, and present in the rat genomic sequence, is absent in mouse due to a single nucleotide difference. Despite its presence in rat, however, we found no evidence, either by RNA-seq analysis or by RT-PCR, that it is ever utilised.
Expression of Cdkl5 in adult tissues and across brain regions
rCdkl5_1 and rCdkl5_2 are the major isoforms detected in the rat brain and are orthologous to human and mouse isoforms _1 and _2, respectively (Fig. 1B, Table 1 ). RT-PCR and quantitative RT-PCR were performed to assess transcript expression across a range of tissues. rCdkl5_1 is expressed most abundantly within the brain, but is also detected in all of the adult tissues tested, showing a similar pattern of expression to that of the mouse, and human ( Fig. 2) (Hector et al., 2016) . rCdkl5_2, which incorporates the highly conserved exon 17, is also expressed primarily in the brain, but can only be detected at lower levels in some other peripheral tissues (Fig. 2) . This also reflects the pattern of expression seen in mouse and human (Hector et al., 2016) . Of the two isoforms expressed in the brain, rCdkl5_1 is the major isoform, as detected by qRT-PCR (Fig. 3) and RNA-seq. rCdkl5_1 is expressed at different levels across different brain regions, with the highest levels detected in the neocortex (Fig. 3) . In contrast, rCdkl5_2 displayed lower but consistent levels of expression across the different brain regions, with modestly elevated levels only in the neocortex (Fig.   3 ). Analysis by qRT-PCR indicates that levels of rCdkl5_2 constitute approximately 20% of Cdkl5 transcripts in the cerebellum and brain stem, but only 5% in the hippocampus, neocortex and striatum (Fig. 3) . Analysis of read count data in RNA-seq datasets estimates that transcripts incorporating exon 17 (rCdkl5_2) constitute approximately 10% of Cdkl5 transcripts expressed in whole brain (Fig. S2) .
Analysis of 5' and 3' regions of Cdkl5 transcripts
The coding regions of rCdkl5_9 and rCdkl5_10 are not orthologous to human or mouse isoforms, due to the use of species-specific exons at the 3' end of the gene (exons 20 and 21; Fig. 1B) . The composition of the 3'-ends of these transcripts had been reported in a previous study by Chen et al. (Chen et al., 2010 ) (where they were known as CDKL5a and CDKL5b), and are confirmed in this study by 3'-RACE (Fig. 4A) . This results in 3'-UTRs of 208 and 162 bases, respectively. 3'-RACE was also used to characterise the 3'-UTRs of rCdkl5_1 and rCdkl5_2. Both of these transcripts were shown to use the same canonical polyadenylation signal identified in human and mouse (Hector et al., 2016) , located 6.8 kb downstream of the stop codon in exon 19 (Fig. 4A ). This yields transcripts of approximately 9.9 and 10 kb in the rat, respectively. A minority of transcripts in the brain were also found to use a more proximal, non-canonical (TATAAA) polyadenylation signal which lies 23 bp upstream of a polyadenylation site at position 35726228 (RGSC 6.0/rn6 genomic reference sequence coordinates). This results in a 3'-UTR of 843 bases.
At the 5' end of the gene, 5'-RACE was used to characterise the TSSs and their contributions to transcript isoforms rCdkl5_1 and _2 (Fig. 4B) . The major TSS (mapped to position 35536407 at the 5'-end of exon 1; rn6, as above) is the same as that identified in orthologous human and mouse transcripts (Hector et al., 2016) , resulting in a highly conserved 5'-UTR of approximately 260 bases. Isoforms rCdkl5_9 and _10, which are predominantly expressed in testis in the adult, use alternative first exons, primarily exon 1a but also 1b (situated approximately 15 kb downstream of exon 1a) (Fig. 4B) . Exon 1a is orthologous to mouse exon 1a and highly conserved; exon 1b, however, is not and evidence from BLAST analysis suggests this to be novel and specific to rat. For exon 1a, a number of (Fig. 4B ).
Discussion
In this study we demonstrate a greater diversity in rat Cdkl5 transcripts than previously realised by identifying and validating all splicing events that occur across a diverse panel of tissues. After elucidating all common and rare splicing events, the majority of the rat Cdkl5 coding region was found to be orthologous and well-conserved with human and mouse, particularly with mouse (Fig. 1) . The diversity arises from alternative first exon usage and alternative splicing to species-specific exons at the 3' end of the gene (Fig. 1 ).
In total, four different coding transcript isoforms in rat Cdkl5 were identified and characterised, and named accordingly with the new nomenclature proposed in our previous study (Hector et al., 2016) . The predominant brain isoform is rCdkl5_1, which is orthologous with the human and mouse isoforms hCDKL5_1 and mCdkl5_1, respectively. The TSS, exon composition, 3'-UTR, polyadenylation signal and site are all well conserved. This contrasts with previous reports, where CDKL5a and CDKL5b were thought to be the major brain isoforms in rat (Chen et al., 2010) . The anti-Cdkl5 antibody used in that study is able to detect all four isoforms identified in this study, so it is possible that the isoforms detected in the brain by western blot were rCdkl5_1 and rCdkl5_2 and not rCdkl5_9 and rCdkl5_10. Our analysis indicates that rCdkl5_9 and rCdkl5_10 are in fact predominantly expressed in the testis, in a similar pattern to hCDKL5_5 in human, and mCdkl5_6, mCdkl5_7 and mCdkl5_8 in mouse. The C-terminal exons in rCdkl5_9 and rCdkl5_10 (named exons 20 and 21) are not clearly orthologous to any conserved human, mouse or other mammalian genomic sequence downstream of the conserved exon 19, according to analysis using BLAST, and it appears that they are specific to rat. The presence of exon 17 in rCdkl5_2 accounts for the only difference between this isoform and rCdkl5_1. The inclusion of this exon adds 41 amino acids to the protein, but although this exon is extremely well conserved between human, mouse and rat, it contains no identified functional elements.
It is apparent that the putative catalytic region of CDKL5, a highly conserved serine/threonine kinase domain in the N-terminal half of the protein, is preserved in all known CDKL5 isoforms in rat, mouse and human (Hector et al., 2016) . The large 3'-UTR (> 6.6 kb) of the major brain isoforms, encoded by exon 19, is also well conserved between human, rat and mouse. Although a number of conserved putative miRNA binding sites in the 3'-UTR can be identified using bioinformatics tools, little else is known about its function. Long 3'-UTRs have been associated with the dendritic trafficking of mRNAs, such as BDNF , and it is possible that the long 3'-UTR of Cdkl5 plays a similar function, as mouse Cdkl5 mRNA has been predicted to have a role in local Cdkl5 synthesis at the dendrites in the adult brain (La Montanara et al., 2015) .
Species-specific diversity is found in the C-terminal region of CDKL5, in coding regions from exons downstream of the highly conserved exon 19. These exons are found in regions of low genomic sequence conservation between rat, mouse and human, and are present only in transcript isoforms that are expressed predominantly in testis (Fig. 1b) . This C-terminal region was originally implicated in the regulation of CDKL5 subcellular distribution (Rusconi et al., 2008) ; however, more recent studies have downplayed the role of these exons in pathogenicity, and therefore function (Diebold et al., 2014) .
Characterising the complexity of Cdkl5 transcripts in more species will aid the understanding of CDKL5 biology in novel animal models as well as facilitating the development of effective, isoform-specific antibodies, the lack of which hampers current research. Careful consideration of this transcript complexity will also be required to inform the development of gene-and protein-based therapies for CDKL5 disorders. and 18. All reads contributing to these data span a maximum of two exons.
